Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment

American Journal of Psychiatry

Volumn 156, Issue 3, 1999, Pages 467-469

  Tsai, Guochuan E ^a   Falk, William E ^b   Gunther, Jeanette ^b   Coyle, Joseph T ^b  

^a MCLEAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; GLUTAMATE RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MEMORY; NEUROTRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; CYCLOSERINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCINE; HUMANS; MALE; MEMORY; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0033015134     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Coyle JT, Price DL, Delong MR: Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-1190
2. Martinez M, Rank A, Diez-Tejedor E, Hernanz A: Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J Neural Transm [Parkinson Dis Sect] 1993; 6:1-9
3. Lowe SL, Bowen DM, Francis PT, Neary D: Antemortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. Neuroscience 1990; 38:571-577
4. 3H] MK-801 binding in Alzheimer's disease. J Neurochem 1989; 53:698-740
5. Patel J, Zinkand WC, Thompson C, Keith R, Salama A: Role of glycine in the N-methyl-D-aspartate-mediated neuronal toxicity. J Neurochem 1990; 54:849-854
6. Chessell I, Procter A, Francis P, Bowen D: D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 1991; 565:345-348
7. Jones RW, Wesnes KA, Kirby J: Effects of NMDA modulation in scopolamine dementia. Ann NY Acad Sci 1991; 640:241-244
8. Tsai GE, Falk WE, Gunther J: A preliminary study of D-cycloserine treatment in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1998; 10:224-226
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
10. Hachinski VC, Hiff LD, Zalkha E: Cerebral blood flow in dementia. Arch Neurol 1975; 32:632-637
11. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145
12. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN: D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 1994; 8:198-205
13. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch SI: D-cycloserine enhances implicit memory in Alzheimer patients. Neurology 1996; 46:420-424
14. Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR: Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 1995; 8:226-230
15. Mohr E, Knott V, Sampson M, Wesnes K, Herting R, Mendis T: Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clin Neuropharmacol 1995; 18:28-38
16. Sano M, Ernesto C, Thomas R: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336:1216-1222